SLC5A2 and diabetes mellitus: The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors as a new class of antihyperglycemics that reduces the risk of adverse cardiovascular and kidney events has been a welcome addition to the armamentarium of therapeutics in diabetes.1,2,3,4,5,6,7 Evidence also suggests that the beneficial effects of SGLT2 inhibitors extend to people without diabetes.8,9,10 However, randomized clinical trials of SGLT2 inhibitors examined the effect of SGLT2 inhibitors vs placebo; the trials did not provide head-to-head comparison with other second-line antihyperglycemic agents.